Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients with metastatic colorectal cancer (mCRC) who progressed after receiving a standard oxaliplatin-based regimen. In this retrospective, single-institution, observational study we collected clinical data from mC...

Full description

Bibliographic Details
Main Authors: Daniele Lavacchi, Giandomenico Roviello, Elisa Giommoni, Lorenzo Dreoni, Silvia Derio, Marco Brugia, Amedeo Amedei, Serena Pillozzi, Lorenzo Antonuzzo
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
aflibercept
colorectal cancer
safety
prognostic factors
bone metastasis
Online Access:https://www.mdpi.com/2072-6694/13/15/3863

Internet

https://www.mdpi.com/2072-6694/13/15/3863

Similar Items